Apple Asks Courts to Ban Some Samsung Smartphone Sales

Samsung Galaxy S II Apple Patent Infringement Case

After winning its patent infringement case against Samsung last Friday, Apple (NASDAQ: AAPL) has now come right back to the courts asking for a preliminary injunction against eight Samsung smartphones that it wants pulled from shelves and banned from sales.  The case, which was decided by a California jury verdict on August 24 after a month-long battle, said that Samsung had infringed upon Apple’s intellectual property for a variety of technologies, including double-tap zooming and scrolling.  Apple said in the lawsuit that Samsung had “slavishly copied” its iPhone and iPads.

Samsung had filed a counterclaim related to its wireless technology that it felt Apple used, but the unanimous decision by the jury in Apple’s favor rejected those allegations.

The judge awarded more than $1 billion to Apple in damages.

Samsung has vowed to challenge the decision all the way to the Supreme Court if necessary, saying it will fight the decision with “all necessary measures.”  As that war wages on, probably before a Washington D.C. court specializing in patent appeals, the verdicts will certainly have the eyes of other major manufacturers and Apple rivals, including Google, a partner of Samsung.  If Apple wins throughout, it could open the door for its arsenal of patents to lead to future cases against Android products and other competitors in the smartphone and tablet markets.

All tallied, the case involved 28 Samsung devices, but the injunction that Apple is immediately seeking for a sales ban only targets eight of the devices that Apple says present an “immediate, ongoing irreparable harm” to the world’s biggest public company.

Those listed by Apple accounted for $1.3 billion in sales for Samsung from the beginning of the year through June and include:

  • Galaxy S 4G
  • Galaxy S II AT&T
  • Galaxy S II T-Mobile
  • Galaxy S II Skyrocket
  • Galaxy S II Epic 4G
  • Galaxy S Showcase
  • Galaxy Prevail
  • Droid Charge

The patent infringements for those eight devices accounted for nearly half of the $1.05 billion awarded to Apple in damages.  The Galaxy S 4G was found to infringe upon the most Apple patents, with seven in total.  Three were related to utility patents, two for design and two claims of trade dress.

For the Samsung faithful, the good news is that the court case did not include the company’s latest flagship products of the Galaxy Note and Galaxy S III.

A ruling on the sales ban is expected to come from the court on September 20.

Apple (AAPL) Stock Quote and News:

Disclaimer: Neither nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at


Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Genesis Completes Acquisitions of ADEX and TNS

Genesis Completes Acquisitions of ADEX and TNS(0)

Utilizing $13 million in proceeds from a MidMarket Capital loan, Genesis Group Holdings, Inc. (OTCBB: GGHO), a holding company operating through its subsidiaries to provide solutions in the telecommunications and mobile industries, reported today that they have completed two acquisitions of revenue generating companies.  The finalized merger will bring Genesis to positive earnings and operational

Growlife to Build Out, Chart at Double Bottom

Growlife to Build Out, Chart at Double Bottom(0)

GrowLife, Inc. recently announced plans to develop as an information portal for the medical marijuana industry. GrowLife, Inc. (OTC: PHOT) (formerly Phototron Holding, Inc.) is a company with core holdings in innovative technology-based products and services for the indoor gardening industry and specialty markets. These brands include Stealth Grow LED producer of hi-powered LED

Cellceutix Cancer Drug Expanding to Three Different Clinical Trials

Cellceutix Cancer Drug Expanding to Three Different Clinical Trials(0)

There is starting to be a steady buzz across the web about Cellceutix Corporation (OTCBB: CTIX) and its novel cancer drug, Kevetrin™.  For starters, the p53-activating drug is on tap to begin dosing patients with solid tumors any day now in clinical trials at the vaunted Harvard University’s Dana-Farber Cancer Institute and partner Beth Israel

Immunovative Quietly Poised to Emerge as Leader in Cancer Vaccines

Immunovative Quietly Poised to Emerge as Leader in Cancer Vaccines(0)

It has long been said that “timing is everything,” but in the case of biotechnology investing, the mantra could not be truer.  There are many different biotech investing styles.  Some traders go after companies with Phase III drug candidates such as Gilead Sciences (NASDAQ: GILD), a company with late-stage drugs that many investors believe will

iMetrik M2M Solutions Heads Towards Full Scale Production and Receives FCC Certification

iMetrik M2M Solutions Heads Towards Full Scale Production and Receives FCC Certification(0)

MarketsandMarkets has released a market research report title, “Machine to Machine (M2M) Market Global Forecast & Analysis” detailing the rapid growth of the emerging field.  According to the report, the total M2M market is expected to reach $85.96 billion by 2017 at a compound annual growth rate (CAGR) of 26.1% from 2012 to 2017. The

read more

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.